Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea

This will be a prospective study in subjects with Obstructive Sleep Apnea (OSA) to characterize the clinical performance during a single night of therapy with a FRESCA mask compared with a single night of therapy with their existing nasal Continuous Positive Airway Pressure (CPAP) mask.

Study Overview

• Status: Completed
• Conditions: Obstructive Sleep Apnea; Sleep Apnea; OSA
• Intervention / Treatment: Device: FRESCA mask first night; Device: CPAP Mask first night

Detailed Description

Obstructive Sleep Apnea (OSA) is a common chronic disorder and the most common of all sleep disorders. OSA can occur in any age group, but prevalence increases between middle and older age. Over the last two decades the prevalence of sleep disordered breathing seems to be increasing in both men and women, likely due to increasing rates of obesity. Relative increases reported are between 14% and 55% depending on the subgroup. For men, the current prevalence estimates of moderate to severe sleep-disordered breathing are 10% for 30 to 49 year-olds and 17% for 50 to 70 year-olds. For women, the corresponding prevalence estimates are 3% and 9%.

Common consequences of OSA include daytime sleepiness, extreme daytime fatigue, slow reaction time, moodiness, belligerence and vision problems. OSA is also linked to hypertension, increased cardiovascular morbidity, type 2 diabetes, neurocognitive dysfunction and possibly cancer.

The study is a prospective, comparative, open label, randomized crossover assignment, multi-center pivotal study.

Up to forty-five (45) subjects will be enrolled. It is desirable to have the subject population distributed across the OSA severity criteria range.

The purpose of this study is to demonstrate that the FRESCA mask is non-inferior to a CPAP nasal mask in maintaining AHI and ODI during a single night of PSG assessment.

• Study Type: Interventional
• Enrollment (Actual): 47
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Fresno, California, United States, 93720
      • Sequoia Sleep Diagnostics
    • Murrieta, California, United States, 92563
      • Complete Sleep Solutions
  • Florida
    • Hollywood, Florida, United States, 33024
      • Broward Research Group
  • New York
    • New York, New York, United States, 10019
      • Clinilabs, Inc
  • South Carolina
    • Columbia, South Carolina, United States, 29201
      • SleepMed of South Carolina

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or Female 18-70 years old;
2. Qualifying diagnostic polysomnography (PSG): Resulting in AHI > 5/hr of sleep (using conventional lab or home test);
3. Qualifying titration PSG: In lab titration within the past 12 months and therapeutic pressure resulting in Apnea Hypopnea Index (AHI) < 5/hr;
4. Primary medical diagnosis of OSA/ Hypopnea syndrome and on CPAP treatment > 1 month;
5. Current user of nasal mask or nasal pillow mask;
6. Have regular usage of their CPAP machine ( at least 4 hrs per night and at least 5 nights per week) confirmed by secure digital (SD) card download;
7. No significant changes in the subject's general health and no change in weight greater than ±10 lbs since titration PSG was performed and CPAP therapy initiated (confirmed from medical records);
8. BMI < 35 kg/m2;
9. Must be able to be fit properly with FRESCA mask;
10. Must be able to comply with all study requirements as outlined in the protocol;
11. Must be able to understand English and be willing to provide written informed consent.

Exclusion Criteria:

1. Subjects with non OSA sleep disorders;
2. Substantial central or mixed apneas (Central and Mixed apnea index ≥ 5/hr);
3. Subjects actively using bi-level PAP or require oxygen therapy;
4. Subjects using a full face mask or chin strap;
5. History of severe cardiovascular disease, including New York Heart Association (NYHA) Class III or IV heart failure, coronary artery disease (CAD) with angina or myocardial infarction (MI)/stroke within past 6 months;
6. Subjects who are medically complicated or who are medically unstable (i.e. cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness);
7. Potential sleep apnea complications that in the opinion of the investigator may affect the health and safety of the participant including: uncontrolled hypertension or hypotension, low blood oxygen (oxygen desaturations nadirs below 75% on their diagnostic PSG), or use of medication or other treatment which may pose additional risk to the subject;
8. Subjects exhibiting any flu-like or any upper airway tract infection symptoms at time of assessment;
9. Subjects with ongoing severe nasal allergies or sinusitis or difficulty breathing through the nose; persistent blockage or one or both nostrils; or any nasal or facial abnormalities that would not allow adequate placement of the device;
10. Subjects with prior surgical intervention for obstructive sleep hypopnea/ apnea syndrome;
11. Currently working nights, rotating night shifts, planned travel across two or more time zones required during study period, or within two weeks prior to study enrollment, or sleep schedule not compatible with sleep lab practices;
12. Unstable use of medications or other agents that may affect sleep or PSG (sedatives or hypnotics);
13. Pregnant (confirmed verbally);
14. Consumption of > 500mg caffeine per day (e.g. > 8 cola-type beverages, > 5 cups of coffee);
15. Currently enrolled in any other research study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FRESCA mask first night; FRESCA mask first night (experimental device) | CPAP second night (active comparator)	Device: FRESCA mask first night; FRESCA nasal mask first night; Device: CPAP Mask first night; CPAP Nasal Mask first night
Experimental: CPAP Mask first night; CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)	Device: FRESCA mask first night; FRESCA nasal mask first night; Device: CPAP Mask first night; CPAP Nasal Mask first night

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Apnea Hypopnea Index (AHI)	The Apnea-Hypopnea Index or Apnoea-Hypopnoea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. Difference of AHI values between patients who used the FRESCA treatment first versus the CPAP treatment.	per hour
Oxygen Desaturation Index (ODI)	The Oxygen Desaturation Index (ODI) is the number of times per hour of sleep that the blood's oxygen level drop by a certain degree from baseline. The ODI is typically measured as part of standard sleep studies, such as a diagnostic polysomnogram, home sleep apnea testing, or with overnight oximetry.Difference of ODI values between patients who used the FRESCA treatment first versus the CPAP treatment.	per hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Arousal Index (AI)	The number of arousals per hour; arousals are defined as a change in EEG for at least 3 seconds.	per hour
Sleep Efficiency (SE%)	Sleep Efficiency (%) [100 x Total sleep time/ total recording time] reported per treatment	per night
Minimum Sleep SpO2 (%)	The minimum O2 level percentage during treatment reported per treatment	per night
Mean Sleep SpO2 -(%)	Mean Sleep SpO2 - blood oxygenation level (%) mean value reported per treatment	per night
Wakefulness (Min)	Measure of time not sleeping (minutes)	per night
Stage N1 (Min)	Stage N1 sleep is an estimate of the degree of sleep fragmentation.	per night
Stage N2 (Min)	Stage N2 sleep predominates the sleep stages with 50% of the total sleep time. It follows the Stage N1 sleep and continues to recur throughout the night.	per night
Stage N3 (Min)	Stage N3 is considered as 'deep sleep'. It is sometimes referred as slow wave sleep.	per night
REM (Min)	The exact function of the REM is uncertain. However, it occupies approximately 25% of the total sleep time. REM sleep cycles occur every 90 to 120 min throughout the night with progressively increasing periods of time. REM sleep is associated with more frequent and longer duration apneas, hypopneas, and severe hypoxemia	per night

Collaborators and Investigators

• Sponsor: FRESCA Medical
• Investigators: Principal Investigator: Atul Malhotra, MD, FRESCA Medical

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Actual): September 1, 2015
• Study Completion (Actual): October 1, 2015

Study Registration Dates

• First Submitted: October 14, 2014
• First Submitted That Met QC Criteria: March 11, 2015
• First Posted (Estimate): March 13, 2015

Study Record Updates

• Last Update Posted (Actual): April 24, 2018
• Last Update Submitted That Met QC Criteria: April 20, 2018
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Signs and Symptoms, Respiratory; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Apnea
• Other Study ID Numbers: 1000-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO